[The effect of combolen on the erythrocyte distribution in the dog].

Abstract

The effect of Combolen (3.9 mg/kg bw s.c.) on the distribution of erythrocytes in dogs was investigated. After application of Combolen, the hematocrit of the animals decreased exponentially within 1 h by 21%. The reversal of the reduction began from 2 h after the time of application, amounting to 4% within the first day and finishing by the fourth day. After injection of 51Cr-labelled erythrocytes, radioactivity in the circulation of Combolen-treated dogs decreased exponentially within 2 h by at least 30%. It was concluded that the dog's spleen, under physiological conditions, contains about 10% of the animal's blood. The time-courses of the decrease of hematocrit and radioactivity in the circulation were found to be very similar. In accordance with this observation, a high correlation (r = 0.97) between the level of radioactivity after injection of radio-labelled erythrocytes and the corresponding hematocrit values after application of Combolen was found. After application of erythrocytes, labelled with 99mTc, an extensive distribution from the circulation into the spleen was observed by scintigraphy. This process can be understood by using a closed-compartment model. An equation, based on this model, describes the observed time course of the hematocrit values, as well as the number of 51Cr-labelled erythrocytes, in Combolen-treated dog. Presumably, the observed effect of Combolen is the result of the relaxation of the smooth muscle cells in the trabeculae of the spleen, caused by central-nervous depression of sympathetic tone. Combolen seems to be a suitable tool in pre-clinical testing of a novel blood preserve with dog as a test animal. Its potent ability to eliminate erythrocytes from circulation is distinguishable from the sequestration of damaged red cells. Furthermore, its ability to prevent the spleen from uncontrolled hematocrit modulating actions in addition to its sedative effects is considered to be an invaluable advantage.